Yet exercise can sometimes be deceptive. Years before starting Virta Health, while cofounding the real-estate company Trulia, Inkinen was an elite Ironman triathlete. He was, and still seems to be, at ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Other possible serious side effects include inflammation of the pancreas, low blood sugar, allergic reactions, kidney problems, gallbladder issues, stomach paralysis, thyroid tumors, or cancer.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed.

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...